CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma

CXCR1 signaling promotes tumor progression in various cancers, and clinical trial has proved efficacy of CXCR1 inhibitor in metastatic breast cancer. Therefore, we investigated the prognostic value of CXCR1 in patients with metastatic renal cell carcinoma (mRCC) receiving tyrosine kinase inhibitors (TKIs) therapy.

Source: Urologic Oncology: Seminars and Original Investigations - January 19, 2018 Category: Urology & Nephrology Authors: Xiang Chen, Li Liu, Jiajun Wang, Zhiyuan Lin, Ying Xiong, Yang Qu, Zewei Wang, Yuanfeng Yang, Jianming Guo, Jiejie Xu Source Type: research